Ibuprofen
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Ibuprofen: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used for inflammatory and painful musculoskeletal conditions such as rheumatoid arthritis, osteoarthritis and juvenile idiopathic arthritis, as well as headache and patent ductus arteriosus. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare skeletal disorder. This prediction currently rests on the model score alone, with no clinical trials and no publications identified in the data compiled for this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Ibuprofen is a well-established NSAID, generally understood to act through cyclooxygenase (COX) inhibition, which reduces prostaglandin-mediated inflammation and pain. Its efficacy in arthritic and musculoskeletal conditions is established.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare skeletal dysplasia caused by loss-of-function mutations in the CDMP1/GDF5 gene, which disrupts BMP/GDF5 signalling in bone and cartilage development. Ibuprofen’s COX inhibition has no established link to this signalling defect. At most, it could provide symptomatic pain relief, which is not disease modification.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between the drug’s musculoskeletal indications and other related skeletal diseases, not biological evidence. The prediction should be treated as a computational hypothesis only.
Other highly ranked predictions show the same pattern. These include brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, brachyolmia, brachydactyly-syndactyly syndrome, pseudoachondroplasia, colobomatous microphthalmia-rhizomelic dysplasia syndrome, hypotrichosis simplex of the scalp, WHIM syndrome and congenital hypotrichosis milia. None has supporting trials or literature in the data compiled. Of these, pseudoachondroplasia is the only one where NSAIDs are already used, as standard supportive care for joint pain rather than as a repurposing finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 3190X | APO-Ibuprofen 400 | Tablet 400 mg (oral) | Not specified in the data compiled |
Safety Considerations
Product-level warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Contraindications and cautions flagged by the knowledge graph (these are drug-disease associations, not label text, and should be verified against the PI):
- Cardiovascular and cerebrovascular: hypertension, hypotension, stroke, cerebral infarction, myocardial infarction
- Gastrointestinal: peptic ulcer disease, inflammatory bowel disease
- Renal and hepatic: kidney disease, liver disease, liver failure, gallbladder disease
- Haematological: thrombocytopenia, blood coagulation disorders
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, hypothyroidism, potassium deficiency
- Other: epilepsy, chronic obstructive pulmonary disease, systemic lupus erythematosus, benign prostatic hyperplasia, substance abuse/dependence
Drug interactions: 100 interactions were recorded. The 20 listed in the data compiled include:
- Major: acetylsalicylic acid (aspirin)
- Moderate: corticosteroids (betamethasone, budesonide, dexamethasone, hydrocortisone), sulfonylureas (acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide), exenatide, aprepitant, balsalazide, fenfluramine, dexfenfluramine, kanamycin, levofloxacin
- Minor: H2 blockers (famotidine, ranitidine, cimetidine)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model (deep learning) score. There are no trials or publications, and no plausible mechanism links COX inhibition to the GDF5/BMP signalling defect underlying this disease. Ibuprofen has a substantial safety profile in vulnerable populations, so there is no basis to advance this indication.
To proceed, the following is needed:
- Mechanism of action data and a credible mechanistic link to the GDF5/BMP pathway
- Preclinical or clinical evidence in this disease, or in a related skeletal dysplasia
- The ARTG approved indication text and TGA Product Information warnings and contraindications
- Assessment of the pending route compatibility and similarity to the original indications
- A clear statement of whether the aim is disease modification or symptomatic pain relief, because the latter is already standard supportive care
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.